Home Newsfeeds Sana Biotechnology Q3 EPS $(0.48) Down From $(0.37) YoY

Sana Biotechnology Q3 EPS $(0.48) Down From $(0.37) YoY

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.48) per share. This is a 29.73 percent decrease over losses of $(0.37) per share from the same period last year.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.48) per share. This is a 29.73 percent decrease over losses of $(0.37) per share from the same period last year.

Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine

By Vandana Singh

July 27, 1:05 PM

Merck & Co Inc (NYSE: MRK) announced topline results from two Phase 3 trials evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve

MRK

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement With UCSF For Innovative Intra-Cerebral Cellular Delivery Platform

By Happy Mohamed

March 28, 4:16 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement

CLPT

Alterity Therapeutics To Host Webcast To Discuss ATH434 Efficacy Data In Primates And Recent Clinical Progress

By Benzinga Newsdesk

December 4, 5:35 PM

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor

ATHE